Ensho Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Ensho Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).
SEC Form D · Oct 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2026
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Ensho Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Danielle Fry | Executive officer | Oct 2026 |
| Bittoo Kanwar | Executive officer | Nov 2024 |
| Danielle Andrew Fry | Executive officer | Nov 2024 |
| Emily Andrew Weng | Executive officer | Nov 2024 |
| James Andrew Whitney | Executive officer | Nov 2024 |
| Matthew Andrew McKevitt | Executive officer | Nov 2024 |
| Neena Bitritto-Garg | Executive officer | Nov 2024 |
| Arash Rassoulpour | Director | Oct 2026 |
| Carlos Solorzano | Director | Oct 2026 |
| Eric Pham | Director | Oct 2026 |
| Gerhard Hagn | Director | Oct 2026 |
| Neena Bitritto-Garg | Director | Oct 2026 |
| Tariq Kassum | Director | Oct 2026 |
| Neena Bitritto-Garg | Promoter | Nov 2024 |